MG4101 Plus Rituximab Including Lymphodepletion in Patient With r/r NHL B-cell Origin

NCT03778619 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

9

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsed Non Hodgkin Lymphoma
Refractory Non-Hodgkin Lymphoma

Interventions

DRUG: Rituximab
DRUG: Fludarabine
DRUG: Cyclophosphamide
BIOLOGICAL: MG4101(allogeneic Natural Killer cell)
DRUG: Interleukin-2

Sponsor

GC Cell Corporation